10x Genomics Stock Alpha and Beta Analysis

TXG Stock  USD 14.31  1.02  7.67%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as 10X Genomics. It also helps investors analyze the systematic and unsystematic risks associated with investing in 10X Genomics over a specified time horizon. Remember, high 10X Genomics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to 10X Genomics' market risk premium analysis include:
Beta
1.38
Alpha
(0.87)
Risk
4.46
Sharpe Ratio
(0.14)
Expected Return
(0.62)
Please note that although 10X Genomics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, 10X Genomics did 0.87  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of 10X Genomics stock's relative risk over its benchmark. 10X Genomics has a beta of 1.38  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, 10X Genomics will likely underperform. At this time, 10X Genomics' Book Value Per Share is most likely to increase significantly in the upcoming years. The 10X Genomics' current Tangible Book Value Per Share is estimated to increase to 6.45, while Enterprise Value Over EBITDA is projected to decrease to (32.21).

Enterprise Value

5.01 Billion

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out 10X Genomics Backtesting, 10X Genomics Valuation, 10X Genomics Correlation, 10X Genomics Hype Analysis, 10X Genomics Volatility, 10X Genomics History and analyze 10X Genomics Performance.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

10X Genomics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. 10X Genomics market risk premium is the additional return an investor will receive from holding 10X Genomics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in 10X Genomics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate 10X Genomics' performance over market.
α-0.87   β1.38

10X Genomics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of 10X Genomics' Buy-and-hold return. Our buy-and-hold chart shows how 10X Genomics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

10X Genomics Market Price Analysis

Market price analysis indicators help investors to evaluate how 10X Genomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading 10X Genomics shares will generate the highest return on investment. By understating and applying 10X Genomics stock market price indicators, traders can identify 10X Genomics position entry and exit signals to maximize returns.

10X Genomics Return and Market Media

The median price of 10X Genomics for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 20.02 with a coefficient of variation of 18.54. The daily time series for the period is distributed with a sample standard deviation of 3.51, arithmetic mean of 18.9, and mean deviation of 3.3. The Stock received a lot of media exposure during the period.
 Price Growth (%)  
       Timeline  
1
Acquisition by Teichmann Sarah A. of 19002 shares of 10X Genomics subject to Rule 16b-3
08/30/2024
2
Disposition of 1000 shares by Serge Saxonov of 10X Genomics at 49.5301 subject to Rule 16b-3
09/06/2024
3
Disposition of 2961 shares by Justin McAnear of 10X Genomics at 22.5297 subject to Rule 16b-3
09/11/2024
4
10x Genomics Expected to Beat Earnings Estimates Can the Stock Move Higher
10/22/2024
5
10x Genomics Inc Reports Q3 2024 Revenue of 151. ...
10/29/2024
6
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
10/30/2024
7
10x Genomics, Inc. Q3 2024 Earnings Call Transcript
10/31/2024
8
10x Genomics Releases Earnings Results, Beats Expectations By 0.04 EPS
11/01/2024
9
10x Genomics Inc Trading 2.45 percent Higher on Nov 4
11/04/2024
10
Disposition of 534 shares by Serge Saxonov of 10X Genomics at 55.064 subject to Rule 16b-3
11/12/2024
11
Disposition of 1350 shares by Serge Saxonov of 10X Genomics subject to Rule 16b-3
11/14/2024
12
10X Genomics stock hits 52-week low at 13.98 amid market shifts - Investing.com
11/15/2024
13
10x Genomics, Inc. Among the Best Genomics Stocks to Buy Right Now
11/20/2024

About 10X Genomics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including 10X or other stocks. Alpha measures the amount that position in 10X Genomics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2021 2022 2023 2024 (projected)
Payables Turnover4.275.5713.3113.97
Days Of Inventory On Hand295.41247.49128.47140.12

10X Genomics Upcoming Company Events

As portrayed in its financial statements, the presentation of 10X Genomics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, 10X Genomics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of 10X Genomics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of 10X Genomics. Please utilize our Beneish M Score to check the likelihood of 10X Genomics' management manipulating its earnings.
15th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with 10X Genomics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:
10X Genomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of 10X Genomics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of 10X Genomics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...